Outcomes

Smilow Cancer Hospital, Bridgeport Hospital and Yale New Haven Health acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. Several types of quality measures have been approved by the Commission on Cancer. Evidence-based measures or accountability measures promote improvements in care delivery and are the highest standard for measurement. These measures demonstrate provider accountability, influence payment for services and promote transparency.

The latest accountability measures for breast and colon cancer at Bridgeport Hospital are listed below.

Breast Measures

Expected Estimated Performance Rates (%) 2014 2015 2016
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability) 90% 99% 95% 92%
Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or stage IB-III hormone receptor positive breast cancer (Accountability) 90% 96% 95% 99%
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability) 90% 100% 83% 100%
Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability) Not applicable 94% 92% 100%

Colon Measures

Expected Estimated Performance Rates (%)
2014 2015 2016
Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer (Accountability) Not applicable 100% 89% 90%